{"success":true,"data":{"pressRelease":{"id":"154765","rtpr_id":"nWkr2qYZzT-20260929","ticker":"8IM1Q","exchange":"","all_tickers":["8IM1Q"],"title":"Implantica's RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception","author":"Cision","published_at":"2026-09-29T06:00:06.448Z","article_body":"Implantica\nImplantica AG (publ.), a medtech company at the forefront of introducing\nadvanced technology into the body, announces RefluxStop® received an\nenthusiastic reception from leading surgeons and gastroenterologists at the\nAmerican Foregut Society (AFS) 2026 Annual Meeting in Washington D.C., marking\nan important milestone in the U.S. launch of RefluxStop®.\n\nFollowing the recent FDA Premarket Approval (PMA) for RefluxStop®, the U.S.\nlaunch kicked off at the AFS Annual Meeting, bringing the Implantica team\ntogether with many of the most esteemed U.S. surgeons and gastroenterologists\n(GIs) specializing in foregut disease. Attendees showed strong interest in\nRefluxStop® and its unique mechanism of action and non-encircling approach to\ntreating GERD, a chronic disease affecting approximately 78 million Americans.\nUnlike traditional anti-reflux surgical procedures that \"wrap\" around the\nesophagus, the RefluxStop® procedure is designed to restore and maintain the\nbody's natural anatomy and physiology to prevent reflux without encircling the\nesophagus. This innovative approach minimizes common post-surgical side\neffects like swallowing difficulties (dysphagia) or the inability to belch or\nvomit.\n\nBuilding on four consecutive years of extensive scientific engagement, the\nRefluxStop® panel discussion at AFS drew an over-booked crowd of 120+\nsurgeons, GIs, and other experts, all eager to learn about this innovative\nsurgical treatment for GERD.\n\nThe panel was moderated by AFS past President, Dr. John Lipham, Chief of the\nDivision of Upper GI and General Surgery, Keck School of Medicine of USC\n(University of Southern California). Dr. Lipham comments:\n\n\"FDA PMA approval of RefluxStop represents a significant milestone and\ninflection point in the evolution of GERD treatment over the past 70+ years.\nSupported by compelling 5-year clinical study results and extensive real-world\nexperience across more than 60 centers from Europe, RefluxStop brings a\ndisruptive, non-encircling approach to millions of GERD patients in the U.S.,\nmany of whom were not ideal candidates for traditional treatments.\" Dr. Lipham\nsums it up, \"The RefluxStop procedure is a major advancement with great\npotential to transform the field of anti-reflux surgery. It was a pleasure to\nwitness the strong interest and growing engagement of my peer experts as\nRefluxStop enters the U.S. healthcare system.\"\n\nThe additional distinguished RefluxStop panelists at the AFS symposium\nincluded doctors from both the U.S. and Europe:\n* Dr. Christy Dunst, AFS President, Medical Director, Heartburn and Foregut\nCenter of Excellence, Hoag Digestive Health Institute, Newport Beach,\nCalifornia\n* Dr. Peter Kahrilas, Past AFS President, Professor of Medicine, Northwestern\nUniversity, Chicago, Illinois\n* Dr. Tripp Buckley, Director of the Center for Heartburn & Esophageal\nDisorders, Surgeon, and Professor of Surgery at University of Texas at Austin,\nAustin, Texas\n* Dr Prakash Gyawali, Professor of Medicine Director, Neurogastroenterology\nand Motility Program, Washington University, St. Louis, Missouri\n* Dr. Walter Chan, Associate Professor of Medicine, Harvard Medical School,\nDirector, Center for Gastrointestinal Motility, Director, Clinical Research\nEducation, Director, Division of Gastroenterology, Hepatology and Endoscopy,\nBrigham and Women's Hospital, Boston, Massachusetts\n* Dr. Felice Schnoll-Sussman, Past AFS President, Professor of Clinical\nMedicine in the Division of Gastroenterology, Director of the Jay Monahan\nCenter for Gastrointestinal Health, New York-Presbyterian & Weill Cornell\nMedicine, New York\n* Dr. Ahmed Ahmed, Clinical Associate Professor in Metabolic Surgery,\nDepartment of Surgery and Cancer, Honorary Consultant, Upper Gastrointestinal\nand Bariatric Surgery, Clinical Lead, Bariatric Surgery, Imperial College\nHealthcare NHS Trust\n* Professor of Surgery, Sebastian Schoppmann, MD, F.A.C.S., Head, Upper GI\nService, Medical University of Vienna, Vienna, Austria, EFS Chairman\n* Dr. Joerg Zehetner, Professor (USC), Specialist, Surgical Director\nSwiss1Chirgurgie, Hirslanden Clinic Beau-Site, Bern, Switzerland\n* Dr. Thorsten Lehmann, Center Director & Chief Physician, Clinics for General\nand Visceral Surgery, Friedrichshafen & Tettnangis, Friedrichshafen, Germany\n* Dr. Moustafa Elshafei, Chief, Department of General and Visceral Surgery,\nMarienhaus Klinikum Mainz, Frankfurt, Germany\nAlso, a recently published paper on the RefluxStop surgical approach, \"How I\ndo it?,\" written by the two largest users of RefluxStop in Germany and\nSwitzerland, published in the Journal of the American Foregut Society\n(Foregut), was among the top trending papers at the meeting.\n\nDr. Peter Forsell, Founder and CEO of Implantica stated, \"The level of\ninterest and enthusiasm in RefluxStop® from leading U.S. surgeons, GIs and\nforegut experts at AFS 2026 was truly remarkable. Our RefluxStop® symposium,\nfeaturing several past and present AFS Presidents alongside other leading\nexperts, reached over-capacity at 120+ attendees, requiring us to close the\ndoors and turn away additional participants. This was followed by nearly 30\none-on-one meetings with me personally and top surgeons and GIs interested in\nintroducing RefluxStop® at their institutions.\"\n\nDr. Forsell continued, \"The exceptional reception at our first major U.S.\nlaunch meeting following FDA approval is very encouraging, and we believe\nreflects the significant unmet need in GERD treatment. With more than 40% of\nU.S. patients continuing to experience symptoms despite daily medication(1),\nwe believe RefluxStop® is perfectly positioned and timed to fill this massive\ntreatment gap and create a new treatment standard for GERD. We are now focused\non the systematic U.S. roll-out and partnering with leading medical\ninstitutions and physicians as they introduce RefluxStop® into clinical\npractice.\"\n1. Delshad, S.D., et al., Prevalence of Gastroesophageal Reflux Disease and\nProton Pump Inhibitor-Refractory Symptoms. Gastroenterology, 2020. 158(5): p.\n1250-1261.e2.\nFor further information, please contact:\nNicole Pehrsson, Chief Corporate Affairs Officer\nTelephone (CH): +41 (0)43 505 2057\nnicole.pehrsson@implantica.com\n\nImplantica is listed on Nasdaq First North Premier Growth Market in Stockholm.\n\nThe company's Certified Adviser is FNCA Sweden AB, info@fnca.se\n\nThe information was sent for publication, through the agency of the contact\nperson set out above, on September 29, 2026, at 08:00 a.m. (CEST).\n\nAbout Implantica\nImplantica is a medtech company focused on bringing advanced implantable\ntechnologies into the body designed to improve patient outcomes and quality of\nlife. The company's lead product, RefluxStop®, is an FDA approved and\nCE-marked implant for the treatment of gastroesophageal reflux disease (GERD)\nwith the potential to transform the standard of care in anti-reflux surgery,\nsupported by strong long-term clinical outcomes.\n\nIn addition to RefluxStop®, Implantica has developed a broad,\npatent-protected product pipeline partly incorporating two platform\ntechnologies: an eHealth platform designed to enable communication with and\nremote monitoring and control of implants inside the body, and a wireless\nenergizing platform designed to wirelessly power implantable devices through\nintact skin. These investigational devices are intended to facilitate remote\nchanges to treatment, potentially saving cost for society.\n\nImplantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP\nA SDB). Visit www.implantica.com for further information.\n\nAbout RefluxStop®\nRefluxStop® is a treatment for GERD designed to address the root cause of\nacid reflux. Conventional anti-reflux surgical procedures typically rely on\nencircling the esophagus and are often associated with side effects such as\nswallowing difficulties, inability to belch or vomit, and gas bloating.\nRefluxStop is different and aims to restore and maintain the lower esophageal\nsphincter in its natural anatomical position without encircling or applying\npressure on the food passageway. Commercial performance from a multitude of\ncenters supports the clinical study data collected and shows that the\nRefluxStop® device can successfully treat GERD without wrapping or\nconstricting the esophageal sphincter, thereby avoiding the side effects\ncommonly seen with the other current treatment approaches. Long-term 5-year\nclinical outcomes on RefluxStop® have been published in peer-reviewed\nscientific journals and support that a significant portion of the patient\npopulation will achieve clinically meaningful results, with minimal risks,\nwhen used in accordance with the indications for use.\n\nIndications for Use: RefluxStop® is an implantable sterile medical device\nintended to treat acid and non-acid reflux in patients diagnosed with\ngastroesophageal reflux disease (GERD). The device ensures maintenance of a\nnormal physiological situation for the gastroesophageal junction (GEJ) in a\ndefined intra-abdominal position, allowing natural physiological function of\nthe lower esophageal sphincter (LES), thereby reducing or eliminating acid and\nnon-acid reflux. The RefluxStop® Deployment Tool is indicated for patients\ndiagnosed with Gastroesophageal Reflux Disease (GERD), defined by abnormal\nimpedance pH and/or pH testing, and indicated for RefluxStop® implantation.\n\nNewsroom\nhttps://www.implantica.com/media/media-kit\n\nCommunity\nhttps://ch.linkedin.com/company/implantica\nhttps://www.twitter.com/implantica\n\nMedia Contact:\nImplantica AG\nJuanita Eberhart, VP Marketing & Advocacy\njuanita.eberhart@implantica.com\n\nhttps://news.cision.com/implantica/r/implantica-s-refluxstop--u-s--market-launch-kicked-off-at-the-2026-american-foregut-society-meeting-%2Cc4401889\n\nImplantica's RefluxStop® U.S. market launch kicked off at the 2026 American\nForegut Society Meeting, receiving an outstanding reception\n(https://mb.cision.com/Main/19732/4401889/4291627.pdf)\n\nlogo transparent 1 8\n(https://news.cision.com/implantica/i/logo-transparent-1-8%2Cc3568435)\n\n\n\n(c) Cision 2026","article_body_html":"","raw_payload":{"data":{"id":"nWkr2qYZzT-20260929","title":"Implantica's RefluxStop® U.S. market launch kicked off at the 2026 American Foregut Society Meeting, receiving an outstanding reception","author":"Cision","ticker":"8IM1Q","created":"2026-09-29T06:00:06.448Z","tickers":["8IM1Q"],"exchange":"","article_body":"Implantica\nImplantica AG (publ.), a medtech company at the forefront of introducing\nadvanced technology into the body, announces RefluxStop® received an\nenthusiastic reception from leading surgeons and gastroenterologists at the\nAmerican Foregut Society (AFS) 2026 Annual Meeting in Washington D.C., marking\nan important milestone in the U.S. launch of RefluxStop®.\n\nFollowing the recent FDA Premarket Approval (PMA) for RefluxStop®, the U.S.\nlaunch kicked off at the AFS Annual Meeting, bringing the Implantica team\ntogether with many of the most esteemed U.S. surgeons and gastroenterologists\n(GIs) specializing in foregut disease. Attendees showed strong interest in\nRefluxStop® and its unique mechanism of action and non-encircling approach to\ntreating GERD, a chronic disease affecting approximately 78 million Americans.\nUnlike traditional anti-reflux surgical procedures that \"wrap\" around the\nesophagus, the RefluxStop® procedure is designed to restore and maintain the\nbody's natural anatomy and physiology to prevent reflux without encircling the\nesophagus. This innovative approach minimizes common post-surgical side\neffects like swallowing difficulties (dysphagia) or the inability to belch or\nvomit.\n\nBuilding on four consecutive years of extensive scientific engagement, the\nRefluxStop® panel discussion at AFS drew an over-booked crowd of 120+\nsurgeons, GIs, and other experts, all eager to learn about this innovative\nsurgical treatment for GERD.\n\nThe panel was moderated by AFS past President, Dr. John Lipham, Chief of the\nDivision of Upper GI and General Surgery, Keck School of Medicine of USC\n(University of Southern California). Dr. Lipham comments:\n\n\"FDA PMA approval of RefluxStop represents a significant milestone and\ninflection point in the evolution of GERD treatment over the past 70+ years.\nSupported by compelling 5-year clinical study results and extensive real-world\nexperience across more than 60 centers from Europe, RefluxStop brings a\ndisruptive, non-encircling approach to millions of GERD patients in the U.S.,\nmany of whom were not ideal candidates for traditional treatments.\" Dr. Lipham\nsums it up, \"The RefluxStop procedure is a major advancement with great\npotential to transform the field of anti-reflux surgery. It was a pleasure to\nwitness the strong interest and growing engagement of my peer experts as\nRefluxStop enters the U.S. healthcare system.\"\n\nThe additional distinguished RefluxStop panelists at the AFS symposium\nincluded doctors from both the U.S. and Europe:\n* Dr. Christy Dunst, AFS President, Medical Director, Heartburn and Foregut\nCenter of Excellence, Hoag Digestive Health Institute, Newport Beach,\nCalifornia\n* Dr. Peter Kahrilas, Past AFS President, Professor of Medicine, Northwestern\nUniversity, Chicago, Illinois\n* Dr. Tripp Buckley, Director of the Center for Heartburn & Esophageal\nDisorders, Surgeon, and Professor of Surgery at University of Texas at Austin,\nAustin, Texas\n* Dr Prakash Gyawali, Professor of Medicine Director, Neurogastroenterology\nand Motility Program, Washington University, St. Louis, Missouri\n* Dr. Walter Chan, Associate Professor of Medicine, Harvard Medical School,\nDirector, Center for Gastrointestinal Motility, Director, Clinical Research\nEducation, Director, Division of Gastroenterology, Hepatology and Endoscopy,\nBrigham and Women's Hospital, Boston, Massachusetts\n* Dr. Felice Schnoll-Sussman, Past AFS President, Professor of Clinical\nMedicine in the Division of Gastroenterology, Director of the Jay Monahan\nCenter for Gastrointestinal Health, New York-Presbyterian & Weill Cornell\nMedicine, New York\n* Dr. Ahmed Ahmed, Clinical Associate Professor in Metabolic Surgery,\nDepartment of Surgery and Cancer, Honorary Consultant, Upper Gastrointestinal\nand Bariatric Surgery, Clinical Lead, Bariatric Surgery, Imperial College\nHealthcare NHS Trust\n* Professor of Surgery, Sebastian Schoppmann, MD, F.A.C.S., Head, Upper GI\nService, Medical University of Vienna, Vienna, Austria, EFS Chairman\n* Dr. Joerg Zehetner, Professor (USC), Specialist, Surgical Director\nSwiss1Chirgurgie, Hirslanden Clinic Beau-Site, Bern, Switzerland\n* Dr. Thorsten Lehmann, Center Director & Chief Physician, Clinics for General\nand Visceral Surgery, Friedrichshafen & Tettnangis, Friedrichshafen, Germany\n* Dr. Moustafa Elshafei, Chief, Department of General and Visceral Surgery,\nMarienhaus Klinikum Mainz, Frankfurt, Germany\nAlso, a recently published paper on the RefluxStop surgical approach, \"How I\ndo it?,\" written by the two largest users of RefluxStop in Germany and\nSwitzerland, published in the Journal of the American Foregut Society\n(Foregut), was among the top trending papers at the meeting.\n\nDr. Peter Forsell, Founder and CEO of Implantica stated, \"The level of\ninterest and enthusiasm in RefluxStop® from leading U.S. surgeons, GIs and\nforegut experts at AFS 2026 was truly remarkable. Our RefluxStop® symposium,\nfeaturing several past and present AFS Presidents alongside other leading\nexperts, reached over-capacity at 120+ attendees, requiring us to close the\ndoors and turn away additional participants. This was followed by nearly 30\none-on-one meetings with me personally and top surgeons and GIs interested in\nintroducing RefluxStop® at their institutions.\"\n\nDr. Forsell continued, \"The exceptional reception at our first major U.S.\nlaunch meeting following FDA approval is very encouraging, and we believe\nreflects the significant unmet need in GERD treatment. With more than 40% of\nU.S. patients continuing to experience symptoms despite daily medication(1),\nwe believe RefluxStop® is perfectly positioned and timed to fill this massive\ntreatment gap and create a new treatment standard for GERD. We are now focused\non the systematic U.S. roll-out and partnering with leading medical\ninstitutions and physicians as they introduce RefluxStop® into clinical\npractice.\"\n1. Delshad, S.D., et al., Prevalence of Gastroesophageal Reflux Disease and\nProton Pump Inhibitor-Refractory Symptoms. Gastroenterology, 2020. 158(5): p.\n1250-1261.e2.\nFor further information, please contact:\nNicole Pehrsson, Chief Corporate Affairs Officer\nTelephone (CH): +41 (0)43 505 2057\nnicole.pehrsson@implantica.com\n\nImplantica is listed on Nasdaq First North Premier Growth Market in Stockholm.\n\nThe company's Certified Adviser is FNCA Sweden AB, info@fnca.se\n\nThe information was sent for publication, through the agency of the contact\nperson set out above, on September 29, 2026, at 08:00 a.m. (CEST).\n\nAbout Implantica\nImplantica is a medtech company focused on bringing advanced implantable\ntechnologies into the body designed to improve patient outcomes and quality of\nlife. The company's lead product, RefluxStop®, is an FDA approved and\nCE-marked implant for the treatment of gastroesophageal reflux disease (GERD)\nwith the potential to transform the standard of care in anti-reflux surgery,\nsupported by strong long-term clinical outcomes.\n\nIn addition to RefluxStop®, Implantica has developed a broad,\npatent-protected product pipeline partly incorporating two platform\ntechnologies: an eHealth platform designed to enable communication with and\nremote monitoring and control of implants inside the body, and a wireless\nenergizing platform designed to wirelessly power implantable devices through\nintact skin. These investigational devices are intended to facilitate remote\nchanges to treatment, potentially saving cost for society.\n\nImplantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP\nA SDB). Visit www.implantica.com for further information.\n\nAbout RefluxStop®\nRefluxStop® is a treatment for GERD designed to address the root cause of\nacid reflux. Conventional anti-reflux surgical procedures typically rely on\nencircling the esophagus and are often associated with side effects such as\nswallowing difficulties, inability to belch or vomit, and gas bloating.\nRefluxStop is different and aims to restore and maintain the lower esophageal\nsphincter in its natural anatomical position without encircling or applying\npressure on the food passageway. Commercial performance from a multitude of\ncenters supports the clinical study data collected and shows that the\nRefluxStop® device can successfully treat GERD without wrapping or\nconstricting the esophageal sphincter, thereby avoiding the side effects\ncommonly seen with the other current treatment approaches. Long-term 5-year\nclinical outcomes on RefluxStop® have been published in peer-reviewed\nscientific journals and support that a significant portion of the patient\npopulation will achieve clinically meaningful results, with minimal risks,\nwhen used in accordance with the indications for use.\n\nIndications for Use: RefluxStop® is an implantable sterile medical device\nintended to treat acid and non-acid reflux in patients diagnosed with\ngastroesophageal reflux disease (GERD). The device ensures maintenance of a\nnormal physiological situation for the gastroesophageal junction (GEJ) in a\ndefined intra-abdominal position, allowing natural physiological function of\nthe lower esophageal sphincter (LES), thereby reducing or eliminating acid and\nnon-acid reflux. The RefluxStop® Deployment Tool is indicated for patients\ndiagnosed with Gastroesophageal Reflux Disease (GERD), defined by abnormal\nimpedance pH and/or pH testing, and indicated for RefluxStop® implantation.\n\nNewsroom\nhttps://www.implantica.com/media/media-kit\n\nCommunity\nhttps://ch.linkedin.com/company/implantica\nhttps://www.twitter.com/implantica\n\nMedia Contact:\nImplantica AG\nJuanita Eberhart, VP Marketing & Advocacy\njuanita.eberhart@implantica.com\n\nhttps://news.cision.com/implantica/r/implantica-s-refluxstop--u-s--market-launch-kicked-off-at-the-2026-american-foregut-society-meeting-%2Cc4401889\n\nImplantica's RefluxStop® U.S. market launch kicked off at the 2026 American\nForegut Society Meeting, receiving an outstanding reception\n(https://mb.cision.com/Main/19732/4401889/4291627.pdf)\n\nlogo transparent 1 8\n(https://news.cision.com/implantica/i/logo-transparent-1-8%2Cc3568435)\n\n\n\n(c) Cision 2026"},"type":"article","timestamp":"2026-09-29T06:00:06.555039995Z","server_sent_at_ms":1790661606555},"received_at":"2026-09-29T06:00:06.625Z","source_url":"https://news.cision.com/implantica/r/implantica-s-refluxstop--u-s--market-launch-kicked-off-at-the-2026-american-foregut-society-meeting-%2Cc4401889"},"analysis":{"id":"143520","press_release_id":"154765","analysis_json":{"industry":{"label":"Health Care Equipment & Supplies","sector":"Health Care"},"redFlags":[],"eventType":"product_launch","narrative":"Implantica kicked off the U.S. market launch of RefluxStop® at the 2026 American Foregut Society Annual Meeting in Washington D.C., following the recent FDA Premarket Approval for the GERD implant.\n\nThe launch symposium drew an over-capacity crowd of 120+ surgeons and gastroenterologists, and CEO Dr. Peter Forsell held nearly 30 one-on-one meetings with top surgeons and GIs interested in introducing RefluxStop® at their institutions.\n\nManagement frames RefluxStop® as positioned to fill a massive treatment gap, noting more than 40% of U.S. GERD patients still experience symptoms despite daily medication, with the company now focused on a systematic U.S. roll-out with leading medical institutions.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"U.S. launch of FDA-approved RefluxStop begins with unusually strong surgeon uptake signals -- watch institutional adoption announcements and first commercial revenue."},"keyFigures":{"drugName":"RefluxStop®","customDimensions":{"panel_attendees":"120+","gerd_patients_us":"approximately 78 million Americans","one_on_one_meetings":"nearly 30","european_centers_real_world":"more than 60 centers","pump_refractory_symptom_rate":"more than 40% of U.S. patients"}},"quotedText":"FDA PMA approval of RefluxStop represents a significant milestone and inflection point in the evolution of GERD treatment over the past 70+ years.","namedEntities":{"people":[{"name":"Dr. Peter Forsell","role":"Founder and CEO of Implantica"},{"name":"Dr. John Lipham","role":"AFS past President, panel moderator, Chief of Upper GI and General Surgery, Keck School of Medicine of USC"},{"name":"Dr. Christy Dunst","role":"AFS President, panelist"},{"name":"Dr. Peter Kahrilas","role":"Past AFS President, panelist"},{"name":"Nicole Pehrsson","role":"Chief Corporate Affairs Officer"},{"name":"Juanita Eberhart","role":"VP Marketing & Advocacy"}],"products":["RefluxStop®"],"companies":[{"name":"Implantica AG (publ.)","ticker":"8IM1Q","relationship":"filer"},{"name":"American Foregut Society","relationship":"medical society / meeting host"},{"name":"FNCA Sweden AB","relationship":"certified adviser"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"U.S. commercial launch of RefluxStop has formally kicked off following FDA PMA approval, with strong surgeon engagement (120+ attendees, ~30 one-on-one meetings with institutions). Commercially meaningful but early-stage with no revenue figures disclosed."},"tickerRelevance":{"others":[],"primary":"8IM1Q"},"globalImportance":30,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap foreign-listed medtech","eventGravity":"commercial launch kickoff post-PMA","householdBrandBoost":0,"retailFavoriteBoost":0}},"event_type":"product_launch","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Implantica kicked off the U.S. market launch of RefluxStop® at the 2026 American Foregut Society Annual Meeting in Washington D.C., following the recent FDA Premarket Approval for the GERD implant.\n\nThe launch symposium drew an over-capacity crowd of 120+ surgeons and gastroenterologists, and CEO Dr. Peter Forsell held nearly 30 one-on-one meetings with top surgeons and GIs interested in introducing RefluxStop® at their institutions.\n\nManagement frames RefluxStop® as positioned to fill a massive treatment gap, noting more than 40% of U.S. GERD patients still experience symptoms despite daily medication, with the company now focused on a systematic U.S. roll-out with leading medical institutions.","key_figures":{"drugName":"RefluxStop®","customDimensions":{"panel_attendees":"120+","gerd_patients_us":"approximately 78 million Americans","one_on_one_meetings":"nearly 30","european_centers_real_world":"more than 60 centers","pump_refractory_symptom_rate":"more than 40% of U.S. patients"}},"named_entities":{"people":[{"name":"Dr. Peter Forsell","role":"Founder and CEO of Implantica"},{"name":"Dr. John Lipham","role":"AFS past President, panel moderator, Chief of Upper GI and General Surgery, Keck School of Medicine of USC"},{"name":"Dr. Christy Dunst","role":"AFS President, panelist"},{"name":"Dr. Peter Kahrilas","role":"Past AFS President, panelist"},{"name":"Nicole Pehrsson","role":"Chief Corporate Affairs Officer"},{"name":"Juanita Eberhart","role":"VP Marketing & Advocacy"}],"products":["RefluxStop®"],"companies":[{"name":"Implantica AG (publ.)","ticker":"8IM1Q","relationship":"filer"},{"name":"American Foregut Society","relationship":"medical society / meeting host"},{"name":"FNCA Sweden AB","relationship":"certified adviser"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-29T06:00:13.300Z","global_importance":30,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap foreign-listed medtech","eventGravity":"commercial launch kickoff post-PMA","householdBrandBoost":0,"retailFavoriteBoost":0}},"durationMs":6590,"modelName":"glm-5.3-flashx"}}